CADILA HEALTHCARE
Cadila Healthcare Limited (also known as Zydus Cadila) is an Indian multinational pharmaceutical company headquartered in Ahmedabad. Cadila was founded in 1952 by Ramanbhai Patel and is primarily engaged in the manufacture of generic drugs. In 1995, group was restructured and thus was formed Cadila Healthcare under the aegis of the Zydus group. Currently, the group has manufacturing sites and research facilities spread across five states of Gujarat, Maharashtra, Goa, Himachal Pradesh and Sikkim in India and in the US and Brazil.
Zydus’ global business has a strong presence in the regulated markets of the US, Europe (France and Spain) and in the high-profile markets of Latin America and South Africa. It is also present in a big way in 25 other emerging markets worldwide.
In July 2020, the company got permission to conduct human trials of the developmental COVID-19 vaccine named ZyCoV-D, from the Drugs Controller General of India (DCGI), Government of India. It will be hitting the markets by June 2021.
Cadila is also among the several Indian pharma companies that received the licensing agreements from the Gilead Sciences to produce remdesivir.
On 27th May 2021, Zydus and TLC sign agreement to market Liposomal Amphotericin B, a critical drug to treat Black Fungus or Mucormycosis in India.
For the quarter ended 31-03-2021, the company has reported a Consolidated revenue from operations of Rs 3846.7 Crore, up by 2.5% when compared with last quarter’s revenue from operations of Rs 3795.6 Crore and up 2.52% from last year same quarter revenue from operations of Rs 3752.1 Crore. Company has reported net profit after tax of Rs 682 Crore in latest quarter. The Board of Directors decided to recommend a Final Dividend @ Rs. 3.50 per equity share of Re. 1/- each for the financial year 2020-21.
The results of Q4 were rectitude.
